MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on October 8, 2004; DOI: 10.1124/mol.104.006569

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.006569v1
67/1/60    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bauman, D. R
Right arrow Articles by Penning, T. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bauman, D. R
Right arrow Articles by Penning, T. M.


Received for publication August 26, 2004.
Revised October 5, 2004.
Accepted for publication October 5, 2004.

Development of non-steroidal anti-inflammatory drug (NSAID) analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: Potential antineoplastic agents that work independently of cyclooxygenase isozymes*

David R Bauman 1, Steven Rudnick 1, Lawrence M Szewczuk 1, Yi Jin 1, Sridhar Gopishetty 1, Trevor M. Penning 1*

1 University of Pennsylvania School of Medicine

* Address correspondence to: E-mail: penning{at}pharm.med.upenn.edu

Abstract

Human aldo-keto reductases (AKRs) regulate nuclear receptors by controlling ligand availability. Enzymes implicated in regulating ligand occupancy and trans-activation of the nuclear receptors belong to the AKR1C family (AKR1C1-AKR1C3). Nuclear receptors regulated by AKR1C members include the steroid-hormone receptors (AR, ER, and PR) and the orphan receptor, PPAR{gamma}. In human myeloid leukemia (HL-60) cells ligand access to PPAR{gamma} is regulated by AKR1C3, which diverts PGD2 metabolism away from J-series prostanoids (Desmond, 2003). Inhibition of AKR1C3 by indomethacin, an NSAID, caused PPAR{gamma} mediated terminal differentiation of the HL-60 cells. To discriminate between anti-neoplastic effects of NSAIDs that are mediated by either AKR1C or COX isozymes, selective inhibitors are required. We report a structural series of N-phenylanthranilic acid derivatives and steroid carboxylates that selectively inhibit recombinant AKR1C isoforms while not inhibiting recombinant COX-1 or COX-2. The inhibition constants, IC50, KI values and inhibition patterns were determined for the NSAID analogs and steroid carboxylates against the AKR1C and COX isozymes. Lead compounds, 4-chloro-N-phenylanthranilic acid and 4-benzoyl-benzoic acid for the N-phenylanthranilic acid analogs and most steroid carboxylates, exhibited IC50 values that had greater than 500-fold selectivity for AKR1C isozymes as compared to COX-1 and COX-2. Crystallographic and molecular modeling studies showed that the carboxylic acid of the inhibitor ligand was tethered by the catalytic Tyr55-OH2+ and explained why A-ring substituted N-phenylanthranilates inhibited only AKR1C enzymes. These compounds can be used to dissect the role of the AKR1C isozymes in neoplastic diseases and may have cancer chemopreventive roles independent of COX inhibition.


Key words: Prostanoid, Sex hormones, PPARs, Structure-activity relationships and modeling, Enzymology, Regulation - transcriptional, Structure/function/mechanism, Cyclooxygenases, Eicosanoids


This article has been cited by other articles:


Home page
 CarcinogenesisHome page
C.-W. Chien, I-C. Ho, and T.-C. Lee
Induction of neoplastic transformation by ectopic expression of human aldo-keto reductase 1C isoforms in NIH3T3 cells
Carcinogenesis, October 1, 2009; 30(10): 1813 - 1820.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y. Nakamura, P. J. Hornsby, P. Casson, R. Morimoto, F. Satoh, Y. Xing, M. R. Kennedy, H. Sasano, and W. E. Rainey
Type 5 17{beta}-Hydroxysteroid Dehydrogenase (AKR1C3) Contributes to Testosterone Production in the Adrenal Reticularis
J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 2192 - 2198.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
J. M Day, H. J Tutill, A. Purohit, and M. J Reed
Design and validation of specific inhibitors of 17{beta}-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis
Endocr. Relat. Cancer, September 1, 2008; 15(3): 665 - 692.
[Abstract] [Full Text] [PDF]

Home page
 ReproductionHome page
B. L Dozier, K. Watanabe, and D. M Duffy
Two pathways for prostaglandin F2{alpha} synthesis by the primate periovulatory follicle
Reproduction, July 1, 2008; 136(1): 53 - 63.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. Qiu, M. Zhou, M. Mazumdar, A. Azzi, D. Ghanmi, V. Luu-The, F. Labrie, and S.-X. Lin
Structure-based Inhibitor Design for an Enzyme That Binds Different Steroids: A POTENT INHIBITOR FOR HUMAN TYPE 5 17beta-HYDROXYSTEROID DEHYDROGENASE
J. Biol. Chem., March 16, 2007; 282(11): 8368 - 8379.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. J. Yee, V. Balsanek, D. R. Bauman, T. M. Penning, and D. Sames
Fluorogenic metabolic probes for direct activity readout of redox enzymes: Selective measurement of human AKR1C2 in living cells
PNAS, September 5, 2006; 103(36): 13304 - 13309.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics